Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.
Patrick Burnett, MD, PhD
Advertisement
Patrick Burnett, MD, PhD, is a board-certified dermatologist and the chief medical officer of Arcutis Biotherapeutics.
Articles by Patrick Burnett, MD, PhD
The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.
Advertisement
Latest Updated Articles
Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr.Published: February 17th 2025 | Updated:
Pipeline Updates on the Horizon From Arcutis BiotherapeuticsPublished: March 6th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Advancing Topical Stewardship and Expanding Nonsteroidal Options
2
Hilary Baldwin, MD, Highlights Emerging Acne and Rosacea Therapies at Elevate-Derm
3
Douglas DiRuggiero, PA-C, DMSc, Recognized at the Elevate-Derm Fall Conference
4
Education and Engagement Drive Momentum in Hair Disorders
5
